French Drug maker Sanofi is getting high hopes from new CEO Olivier Brandicourt. A new insulin Toujeo is expected a fair approval from USA FDA and may soon get US Patent and copyrights. Company has lost much sales volume after losing its patent on Lantus insulin.
Olivier is struggling new ways to boosts sales volume. He is launching campaign to get doctors prescribe new Toujeo. On the other side also coordinating with insuring companies to undertake new rules for patients.
New Chief Executive of company has previously worked with Bayer AG's Health Care and Pfizer. He was discharged due to unknown reasons. Few comment that his lack of control and management is main reason for 59 year old CEO.
Lantus is Sanofi leading diabetes control insulin and took company to second largest selling position after Novo Nordisk A/S. Recent research study of market capital by EvaluatePharma showed that Diabetes market is more than $38 billion a year. And is largest among all other disease's drug sale.
Related Articles:
Olivier is struggling new ways to boosts sales volume. He is launching campaign to get doctors prescribe new Toujeo. On the other side also coordinating with insuring companies to undertake new rules for patients.
New Chief Executive of company has previously worked with Bayer AG's Health Care and Pfizer. He was discharged due to unknown reasons. Few comment that his lack of control and management is main reason for 59 year old CEO.
Lantus is Sanofi leading diabetes control insulin and took company to second largest selling position after Novo Nordisk A/S. Recent research study of market capital by EvaluatePharma showed that Diabetes market is more than $38 billion a year. And is largest among all other disease's drug sale.
Related Articles:
